A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Phase of Trial: Phase IV
Latest Information Update: 06 Jan 2017
Price : $35 *
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms PROVENGE
- 03 Jan 2017 Status changed from active, no longer recruiting to completed.
- 08 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 08 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.